JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Stock List・Innoviva Inc

Innoviva Inc

Closed

SectorHealthcare

22.63 -1.52

Buy Sell

Overview

Share price change

24h

Current

Min

22.63

Max

23.17

Key metrics
By Trading Economics
Income	152M 242M
Sales	10M 118M
P/E Sector Avg	7.079 67.147
Profit margin	204.74
Employees	159
EBITDA	100M 208M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+60.94% upside

Dividends
By Dow Jones
Next Earnings	12 May 2026

Market Stats
By TradingEconomics
Market Cap	70M 1.7B
Previous open	24.15
Previous close	22.63

News Sentiment

By Acuity

20%

80%

53 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

18.57 / 18.75 Support & Resistance

Innoviva Inc Chart

Past performance is not a reliable indicator of future results.

Related News

5 May 2026, 23:43 UTC

Major News Events

New Zealand's Unemployment Rate Falls in 1Q

5 May 2026, 23:20 UTC

Hot Stocks

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 May 2026, 21:48 UTC

Earnings

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 May 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 May 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 May 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 May 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5 May 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 May 2026, 22:08 UTC

Earnings

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 May 2026, 22:07 UTC

Earnings

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 May 2026, 21:48 UTC

Earnings

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 May 2026, 21:48 UTC

Earnings

Pan American Silver 1Q Rev $1.2B >PAAS

5 May 2026, 21:42 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 May 2026, 21:38 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 May 2026, 21:30 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 May 2026, 21:29 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 May 2026, 21:26 UTC

Earnings

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 May 2026, 21:25 UTC

Earnings

Alcon Inc. 1Q EPS 39c >ALC.EB

5 May 2026, 21:25 UTC

Earnings

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 May 2026, 21:24 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 May 2026, 21:18 UTC

Earnings

Mistras Backs 2026 Rev $730M-$750M >MG

5 May 2026, 21:17 UTC

Earnings

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 May 2026, 21:15 UTC

Earnings

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 May 2026, 21:12 UTC

Earnings

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 May 2026, 21:11 UTC

Earnings

SSR Mining 1Q Rev $581.8M >SSRM

5 May 2026, 21:10 UTC

Earnings

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 May 2026, 21:10 UTC

Earnings

SSR Mining 1Q EPS $1.16 >SSRM

5 May 2026, 21:08 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 May 2026, 21:01 UTC

Earnings

Intact Financial 1Q EPS C$4.12 >IFC.T

5 May 2026, 21:01 UTC

Hot Stocks

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Peer Comparison

Price change

Innoviva Inc Forecast

Price Target

By TipRanks

60.94% upside

12 Months Forecast

Average 37 USD 60.94%

High 46 USD

Low 32 USD

Based on 4 Wall Street analysts offering 12 month price targets forInnoviva Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Innoviva Inc - Dist in the past 3 months.

Technical Score

By Trading Central

18.57 / 18.75Support & Resistance

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

53 / 347 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.